# A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

> **NCT00585000** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 49 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** CP-675,206

## Key facts

- **NCT ID:** NCT00585000
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585000, "A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00585000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*